PRFX
PRF Technologies Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.71
−8.88%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -87.6%
- EBIT
- —
- EPS
- +80.6%
- Free cash flow
- -23.8%
- Operating cash flow
- -23.8%
Forward estimates
Based on analyst estimates
- Revenue
- -44.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -41.7%
- EBITDA
- +71.0%
- EBIT
- +66.0%
- Net income
- +66.8%
- EPS
- +99.1%
- Free cash flow
- +68.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026